Introduction
============

Oxidative DNA damage appears to cause either mutagenesis or cell death, thereby resulting in various age-related diseases such as cancer and multi-organ dysfunction [@B1]. 8-oxoguanine (8-oxoG), which is the major modified base found in the oxidized DNA, is highly mutagenic DNA lesion since DNA polymerases incorporate adenine as well as cytosine opposite 8-oxoG with almost equal frequency, thereby causing G:C to T:A transversion [@B2]. In mammalian cells, 8-oxoG-related mutagenesis is prevented by MTH1, OGG1 and MUTYH. MTH1 has an 8-oxo-dGTPase activity hydrolyzing 8-oxo-dGTP to monophosphate form; 8-oxo-dGMP, thus preventing incorporation of 8-oxo-dGTP into DNA [@B3][@B4], and found that MTH1 protein plays a crucial role in suppressing spontaneous mutagenesis as well as carcinogenesis [@B5][@B6]. OGG1 is a DNA glycosylase that excises 8-oxoG paired with cytosine, and suppress spontaneous and UV-induced tumorigenesis in mammal [@B7][@B8][@B9][@B10][@B11][@B12]. MUTYH removes adenine misincorporated opposite 8-oxoG and also removes 2-hydroxyadenine (generated by oxidation of adenine) misincorporated opposite guanine [@B13][@B14]. We previously established *Mutyh*-deficient mice [@B15][@B16], and showed that *Mutyh*-deficient mice had susceptibility to tumorigenesis, especially adenoma and adenocarcinoma in the intestinal tracts [@B17]. We also showed that oral administration of KBrO~3~, an oxidizing agent known to induce the 8-oxoG in the genome, dramatically enhanced the tumor-formations in small intestines of *Mutyh*-deficient mice [@B17].

MUTYH-associated polyposis (MAP) is a human hereditary colorectal polyposis caused by biallelic-inherited mutations in *MUTYH* [@B18][@B19]. The clinical features of MAP resemble to attenuated familial adenomatous polyposis (AFAP) characterized with less polyps and later onset than familial adenomatous polyposis (FAP) [@B20][@B21][@B22]. A significant number of patients clinically diagnosed as adenomatous polyposis without germline mutations in *APC* are considered to carry *MUTYH* mutations. In most cases, polyps developed in MAP patients had mutations in *APC*, almost all of those were G:C to T:A transversions with the frequent occurrence in AGAA or TGAA sequence [@B18][@B23][@B24].

APC is an important factor of the canonical Wnt-signaling pathway, and *APC* mutations cause a failure in phosphorylation of β-catenin by glycogen synthase kinase 3 beta (GSK3β), resulting in the stabilization of β-catenin and its accumulation in nucleus without Wnt signal. High level of β-catenin in nucleus leads to up-regulation of various genes for such as c-Myc and Cyclin D1 with T-cell factor/lymphoid enhancing factor (TCF/LEF) [@B25][@B26]. *APC* is also known as the tumor suppressor gene, germline mutation of which is responsible for FAP [@B27][@B28]. Somatic *APC* mutations were found in more than 80% of sporadic colorectal cancers (CRCs) and *CTNNB1* (β-catenin*)* mutations were also found in about a half of CRCs lacking *APC*mutation [@B25][@B29][@B30]. Because *APC* and *CTNNB1* mutations are mutually exclusive, it is considered that each mutation has nearly equal effect on β-catenin stability and TCF/LEF transactivation, albeit some differences such as the effect on invasiveness [@B31]. Accordingly, unrestrained activation of the Wnt signaling pathway, resulted from the mutations in *APC* or in *CTNNB1*, is considered to be associated with early premalignant lesion, such as aberrant crypt foci and small polyps [@B32].

In addition to *APC* or *CTNNB1*, mutations in *KRAS* and *TP53* are frequently found in colorectal cancer in human. *KRAS* mutations, mainly at codon 12, were found in approximately a half of colorectal cancers [@B26][@B33][@B34]. *TP53* (official symbol: *TP53* in human, and *Trp53* in mouse) is a tumor suppressor gene involved in various cellular functions, such as cell-cycle control, apoptosis and maintenance of genetic stability. Defects of *TP53*, resulting from mutations or loss of heterozygosity, were found in many of colorectal cancers [@B35][@B36]. *KRAS* mutations, but not *TP53* mutations, are commonly observed in tumors from MAP patients [@B37][@B38].

In this study, we performed pathological evaluation among the small intestinal tumors developed in wild-type and *Mutyh*-deficient mice treated with KBrO~3~ according to the Vienna classification of gastrointestinal epithelial neoplasia [@B39]. To gain an insight into the process of the oxidative stress-induced tumor-development in *MUTYH*-deficient genetic background, we analyzed mutations in the tumor-associated genes, such as *Apc*, *Ctnnb1*, *Kras* and *Trp53* in the tumors developed in wild-type and *Mutyh*-deficient mice treated with KBrO~3~.

Materials and methods
=====================

Animals and KBrO~3~ treatment
-----------------------------

*Mutyh*-deficient mice used in this study were previously generated, and backcrossed to C57BL/6J for more than 10 generations [@B17]. Genomic DNA samples and histological slides of the small intestinal tumors were prepared from the mice treated with KBrO~3~ as previously reported [@B17]. Briefly, wild-type C57BL/6J mice or congenic *Mutyh*-deficient mice were treated with 0.2% KBrO~3~ in drinking water for 16 weeks. Body weight and amount of water consumption were measured once a week. At the end of the KBrO~3~-treatment, mice were sacrificed and the tissues were fixed with 4% buffered-formaldehyde and then stored in 70% ethanol. All animals were kept in specific pathogen free (SPF) conditions. All animal care and handling procedures were approved by the Institutional Animal Care and Use Committee of Kyushu University, and followed the Guideline for Proper Conduct of Animal Experiments, Science Council of Japan.

Preparation of DNA from small intestinal tumor
----------------------------------------------

Inspections of the small intestines were carefully carried out and the small intestinal tumors were removed under dissecting microscope. Preparations of DNA from the removed tumors were performed using DNeasy Tissue Kit (QIAGEN) according to the manufacturer\'s protocol.

PCR and DNA sequencing
----------------------

Sixty-two small intestinal tumors obtained from 4 *Mutyh*-deficient mice were used for mutation analysis of *Apc, Ctnnb1*, *Kras* and *Trp53*, while 11 tumors developed in wild-type mice were analyzed for mutations only in *Ctnnb1*. Thirty- to fifty-nanogram of genomic DNA from each small intestinal tumor was used as the template for PCR. Amplified DNA was purified with QIAquick PCR Purification Kit (QIAGEN) according to the manufacturer\'s protocol. The purified DNA fragments were used as the template for direct sequencing with BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and the sequences were determined with ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems). In the case of detecting two mutations in *Apc* from one tumor, we performed PCR with new primer sets designed for amplifying the fragment encompassing both mutation sites. The DNA fragments amplified with PrimeSTAR HS DNA polymerase (TAKARA) were inserted into the EcoRV site in pBluescript II SK(-) (Stratagene) and the cloned fragments were used as templates for sequencing. In the case of deletion found by direct sequencing, we confirmed the deleted region by sequencing using cloned amplified fragment as template. The information of the primers used and PCR conditions are available upon request.

Histological analysis
---------------------

The small intestinal tumors were removed, embedded in paraffin and sectioned (3 µm). After being deparaffinized and re-hydrated, the sections were stained with hematoxylene and eosin. The evaluation of the tumors was performed according to the Vienna classification [@B39].

Immunohistochemistry
--------------------

Immunohistochemistry were performed on 3 µm thick paraffin-embedded sections of the small intestinal tumors with anti-β-catenin antibody. The sections were deparaffinized in xylen and re-hydrated through graduated ethanol at room temperature. Tissue sections were soaked in 10 mM citrate buffer (pH6.0) and then subjected to antigen retrieval by microwaving for 20 minutes before the primary antibodey reaction. After treatment with 3% hydrogen peroxide for 5 minutes and 50 mM Tris-HCl (pH7.5) containing 1% BSA for 15 minutes, a 1:4000 diluted rabbit polyclonal anti-β-catenin antibody (Sigma) was applied to the sections, and incubated either at room temperature for 1 hr or at 4°C overnight. The detections were carried out with avidin-biotin-enzyme complex (ABC) method using LSAB+ System-HRP (DAKO) according to the manufacturer\'s protocol. The tumors with more than 5% of nuclear stained cells were counted for positive.

Results
=======

Pathological analysis of small intestinal tumors
------------------------------------------------

We performed pathological analysis of 73 and 10 small intestinal tumors derived from *Mutyh*-deficient (n=4) and wild-type mice (n=10), respectively (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). The tumors had predominantly developed in the oral side of the small intestine. The sizes of the tumors developed in wild-type mice were apparently smaller than those in *Mutyh*-deficient mice. All tumors showed non-polypoid growth and their height was almost equal to normal villi. All the tumors showed cytological changes such as variably sized and enlarged nuclei, and also showed architectural changes with keeping the fundamental structure of glands, while no tumors showed evident invasion. Based on the Vienna classification of gastrointestinal epithelial neoplasia, all of these tumors were classified as category 4 (non-invasive high grade neoplasia), except for one case in a wild-type mouse that was classified as category 3 (non-invasive low grade neoplasia) because of milder cytological and architectural changes.

Somatic *Apc* mutations in the small intestinal tumors
------------------------------------------------------

To analyze *Apc* mutation, we amplified and sequenced the 5\'-region of exon 15 of *Apc*, because many somatic mutations in this region were identified in the tumors from MAP patients [@B18][@B23]. Using 10 overlapping primer sets, the targeting region of *Apc* was amplified and used as templates for direct sequencings. We analyzed 62 tumors developed in 4 *Mutyh*-deficient mice treated with KBrO~3~. Twenty-five somatic mutations from 18 tumors were detected, and all the mutations were identified as G:C to T:A transversions, leading to the non-sense mutations (Table [2](#T2){ref-type="table"}). Seventeen out of 25 mutations (68.0%) were found in the AGAA or TGAA sequences. Because 7 tumors displayed two mutations in the region analyzed, we examined whether these two mutations occurred in the same allele or not. After PCR amplification using specific primer sets for amplifying the fragment simultaneously covering the region of the two mutations, the amplified fragments were cloned into plasmid vectors. The sequence analyses of these plasmid clones revealed that no clones simultaneously carried both two mutations, thus demonstrating that these tumors were compound-heterozygotes in *Apc* alleles.

Somatic *Ctnnb1* mutations in the small intestinal tumors
---------------------------------------------------------

β-catenin is reported to have 4 putative GSK3β-phosphorylation sites. Phosphorylation of β-catenin by GSK3β in a complex with Axin and Apc is required to target β-catenin for degradation by the proteasome. Therefore, the mutations at the phosphorylation sites of β-catenin are considered to be related to its stability that would lead to the accumulation of β-catenin in nuclei, thereby up-regulating the expression of the target genes. In addition, the region of mouse (but not human) *Ctnnb1*encoding GSK3 β-phospharylation sites of β-catenin contains AGAA sequences. Therefore, we analyzed mutations in exon 3 of *Ctnnb1* encoding GSK3β-phospharylation sites of β-catenin. Among 62 tumors from 4 *Mutyh*-deficient mice and 11 tumors from 10 wild-type mice, 36 out of 62 tumors (58.1%[)]{.ul} from *Mutyh*-deficient mice and 3 out of 11 tumors (27.3%) from wild-type mice showed a mutation in the region corresponding to the GSK3β-phosphorylation sites (Table [3](#T3){ref-type="table"}). All the mutations in *Mutyh*-deficient mice were base substitution mutations, in which 35 mutations (97.2%) were identified as G:C to T:A transversions and 1 mutation (2.8%) as A:T to T:A transversion. Remarkably, 34 G:C to T:A transversions occurred at the AGAA sequences associated with either Ser33 or Ser37, the putative phosphorylation sites, changing them to tyrosine. Two mutations found on either side of codon for Ser33, which converted the original amino acids (Asp32 or Gly34) to Valine. No tumor carried mutations in both *Apc* and *Ctnnb1* genes, simultaneously. In wild-type mice, 2 base substitution mutations and a 24-bp-deletion were identified. Both base substitution mutations were G:C to A:T transitions, not related to 8-oxoG-induced transversions. One of them occurred at Ser41 changing it to Isoleucine, where no mutation was found in *Mutyh*-deficient mice.

No tumors had mutations in either Kras or Trp53
-----------------------------------------------

It has been shown that *KRAS* mutations were common in tumors developed in MAP patients, and all the mutations were G:C to T:A transversions at first G of codon12 [@B37][@B38]. In addition, *TP53* muations were also detected in tumors from MAP patients, albeit at relatively low frequency [@B37]. Thus, we further searched for the mutations in exon 2 of *Kras* (containing codon 12 and 13) and in exon 5 to 8 of *Trp53* (conserved region) in tumors from KBrO~3~-treated *Mutyh* mice. Neither *Kras* nor *Trp53* mutations was found in the regions analyzed.

Immunohistochemistry
--------------------

Mutations occurred both in *Apc* and in *Ctnnb1* would result in the accumulation of β-catenin in the nucleus. To verify this possibility, immunohistochemistry for β-catenin was performed with 71 small intestinal tumors developed in the 4 *Mutyh*-deficient mice treated with KBrO~3~. The tumors with more than 5% of nuclear stained cells were counted for positive. Nuclear staining was identified in 41 tumors (57.7%), indicating the accumulation of β-catenin in the nuclei (Figure [2](#F2){ref-type="fig"}). These findings support the results of mutation analysis in *Apc* and *Ctnnb1*.

Discussion
==========

We previously reported that *Mutyh*-deficient mice showed the susceptibility to tumorigenesis, especially adenoma/carcinoma in the intestine, hemangioma in the liver and angiosarcoma in the spleen [@B17]. The intestinal tumor susceptibility of *Mutyh*-deficient mice was further enhanced by treatment with KBrO~3~, a known oxidative renal carcinogen associated with 8-oxoG accumulations. The multiple tumor-formation in the mutant mice is consistent with the malignant capacity of multiple colorectal adenomatous polyposis in MAP patients, suggesting that *Mutyh*-deficient mouse is an animal model for investigating the pathogenesis of MAP. Thus, we performed the characterization of tumors induced in *Mutyh*-deficient mice treated with KBrO~3~.

The small intestinal tumors analyzed in this study were exclusively classified in category 4 according to the Vienna classification of gastrointestinal neoplasia (Table [1](#T1){ref-type="table"}). Only one tumor developed in a wild-type mouse with KBrO~3~-treatment was classified in category 3. Even the tiny tumors were also classified in category 4. These results suggested that the KBrO~3~-induced small intestinal tumors show significantly dysplastic change in the early stage of tumor-development. This gives rise to a possibility that the chronic exposures of KBrO~3~ to intestinal mucosa in *Mutyh*-deficient mice might evoke concurrent mutations in multiple genes, although we could find any mutations neither in *Kras* nor in *Trp53*.

Tumors from MAP patients exhibit a significantly increased incidence of G:C to T:A somatic mutations in *APC*. These mutations exclusively occurred in AGAA or TGAA sequences. We examined mutations in the region of *Apc* in which many somatic mutations were identified in tumors from MAP patients, and found 25 somatic mutations in 18 out of 62 tumors. All the mutations were characterized as G:C to T:A transversions, and 68.0% (17 out of 25) of the mutations were found at either AGAA or TGAA sequence. These results are highly consistent with the findings in the tumors developed in MAP patients. We also analyzed *Ctnnb1* for incidence of mutations because *CTNNB1* mutations were found in about a half of colorectal cancers lacking *APC* mutation in humans [@B25][@B29][@B30]. We identified 36 mutations (35 G:C to T:A transversions and 1 T:A to A:T transversion) in *Ctnnb1* among 62 tumors. All the G:C to T:A transversions detected in *Ctnnb1* occurred at the GAA sequence, 34 in AGAA and one in second G of GGAA sequences. Fifty-four out of 62 (87.1%) tumors developed in KBrO~3~-treated *Mutyh*-deficient mice carried mutations either in *Apc* or *Ctnnb1*. The immunohistochemistry confirmed β-catenin accumulation in the nuclei of the tumors harboring either *Apc* or *Ctnnb1* mutations. These observations suggest the association between the defect in the Wnt-signaling pathway and multi-tumor formation in *Mutyh*-deficient mice treated with KBrO~3~. On the other hand, we could not detect any *Kras* mutations in the KBrO~3~-induced tumors, although *KRAS* mutations in codon12 were frequently observed in the cancers (64%) and adenomas (43%) of MAP patients [@B37], [@B38]. These differences may be attributed to a short period (16 weeks) for tumor-formation under the consecutive and enhanced oxidative stress in *Mutyh*-deficient mice. It is also possible that *Kras* mutation may occur at a relatively late stage in multistep carcinogenesis, so that the mutation, if any, could not be detected with the methods we applied in this study.

We also examined for *Ctnnb1* mutations in the small intestinal tumors developed in wild-type mice. None of the mutations was G:C to T:A transversion; two were G:C to A:T transitions and one was a 24-bp deletion. Thus, the mutations found in the KBrO~3~-treated wild-type mice would not result from the mutagenic effects of 8-oxoG. These results indicates that Mutyh can sufficiently suppress the appearance of premalignant cells containing G:C to T:A transversions in wild-type mouse, even under the condition of enhanced oxidative stress.

The small intestinal tumors induced by KBrO~3~-treatment displayed more mutations in *Ctnnb1* than in *Apc*, although *APC* mutation is mostly common in human colorectal cancer and MAP polyps. GSK3β-phosphoryration sites and their surroundings of β-catenin are highly conserved; there are no difference of amino acid sequence in the region between human and mouse. However, there are some differences in the DNA sequence corresponding to this region. In this study, *Ctnnb1* mutations were frequently found in the codon for Ser33 and the corresponding DNA sequence is TCT in both human and mouse. There is a TTC sequence spanning codon 32 and 33 in mouse *Ctnnb1* but not in human *CTNNB1* because of the difference in codon-usage for Asp32; GAT in mouse but GAC in human. Because AGAA sequences (and its reverse-complementary sequence TTCT) appear to be the target sites for oxidative stress-induced mutagenesis in *MUTYH*-deficient genetic background, it is conceivable that this difference would be a main reason why *Ctnnb1* mutations were predominantly observed in the tumors from *Mutyh*-deficient mice.

The observed high incidence of mutations either in *Apc* or *Ctnnb1* imply that the initial event of tumor-formation would be a dysfunction of Wnt-signal pathway in intestinal epithelial cells of *Mutyh*-deficient mice treated with KBrO~3~. Our study further demonstrated that in agreement with the findings in MAP, G:C to T:A transversions were detected in the genes controlling Wnt-signal pathway with high frequency, and the mutations predominantly occurred at AGAA or TGAA sequences. Thus, in addition to the multiple tumor-formation in the mutant mice, specificity with respect to the genetic defects and its mutational spectra and specificity are also considerably match to the observations in the multiple colorectal adenomatous polyposis in MAP patients. We, therefore, consider that KBrO~3~-induced tumorigenesis using *Mutyh*-deficient mice is a useful experimental system for studying on molecular processes in the early development of adenoma and carcinoma in MAP, as well as for examining the preventive and therapeutic approaches for the oxidative stress-induced intestinal tumors [@B40].
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![H.E. staining of the KBrO~3~-induced small intestinal tumors developed in *Mutyh*-deficient and wild type mouse. (**A**) One of the typical tumors from *Mutyh*-deficient mouse; classified as category 4. (**B**) An exceptional case classified as category 3 developed in wild-type mouse. Magnifications are indicated in lower right of the photos.](ijbsv10p0940g001){#F1}

![Immunohistochemistry for β-catenin. Many nuclear steins are observed in tumor cells but not in normal cells. The junctions of epithelial cells are also well stained. Magnifications are indicated in lower right of the photos.](ijbsv10p0940g002){#F2}

###### 

Pathological evaluation of KBrO~3~-induced small intestinal tumors

                           Category 3   Category 4   Total       
  ------------------------ ------------ ------------ ------- --- ----
  Wild type mice           1            3            6       0   10
  *Mutyh*-deficient mice   0            2            71      0   73

NOTE: The numbers in the table indicates the number of the tumors classified as each category. This evaluation was performed according to the Vienna classification of gastrointestinal neoplasia. Category 3: non-invasive low grade neoplasia, Category 4: non-invasive high grade neoplasia (4.1: high grade adenoma/displasia, 4.2: non-invasive carcinoma, 4.3: Suspicion of invasive carcinoma).

###### 

Somatic *Apc* mutations in the small intestinal tumors

  Mouse ID^1)^   Tumor ID^2)^   Nucleic acid change^3)^   Amino acid change^4)^   Secuence context^5)^
  -------------- -------------- ------------------------- ----------------------- --------------------------
  44f            1              93828 G→T                 E1396X                  T**G**AG
  44f            5              92805 G→T                 E1055X                  A**[G]{.ul}**[AA]{.ul}
  44f            6              93226 C→A                 S1195X                  *T**[G]{.ul}**[AA]{.ul}*
  44f            6              93405 G→T                 E1255X                  A**[G]{.ul}**[AA]{.ul}
  44f            9              92607 G→T                 E989X                   T**[G]{.ul}**[AA]{.ul}
  44f            9              93481 C→A                 S1280X                  *T**G**AT*
  44f            10             93141 G→T                 E1167X                  T**[G]{.ul}**[AA]{.ul}
  44f            13             93343 C→A                 S1234X                  *T**[G]{.ul}**[AA]{.ul}*
  50m            22             93220 C→A                 S1193X                  *T**G**AT*
  50m            24             92694 G→T                 E1018X                  A**[G]{.ul}**[AA]{.ul}
  50m            24             93708 G→T                 G1356X                  A**G**GA
  50m            25             92550 G→T                 G970X                   T**G**GA
  50m            28             92805 G→T                 E1055X                  A**[G]{.ul}**[AA]{.ul}
  50m            28             93667 C→A                 S1342X                  *T**[G]{.ul}**[AA]{.ul}*
  50m            29             92805 G→T                 E1055X                  A**[G]{.ul}**[AA]{.ul}
  50m            29             92238 G→T                 E853X                   AGAG
  50m            30             93042 G→T                 E1134X                  T**[G]{.ul}**[AA]{.ul}
  50m            30             93099 G→T                 E1153X                  A**[G]{.ul}**[AA]{.ul}
  56f            33             93099 G→T                 E1153X                  A**[G]{.ul}**[AA]{.ul}
  56f            46             93492 G→T                 E1284X                  T**[G]{.ul}**[AA]{.ul}
  56f            48             92826 G→T                 E1062X                  C**G**AG
  56f            48             93102 G→T                 E1154X                  A**[G]{.ul}**[AA]{.ul}
  124m           49             92811 G→T                 E1057X                  T**[G]{.ul}**[AA]{.ul}
  124m           54             93498 G→T                 G1286X                  A**G**GA
  124m           60             92199 G→T                 E853X                   A**[G]{.ul}**[AG]{.ul}

NOTE: 62 tumors from 4 *Mutyh*-deficient mice were analyzed for *Apc* mutation.

^1)^ The 4 *Mutyh*-deficient mice consisting of two males and two females were analyzed.

^2)^ ID number of tumors carrying mutations in *Apc*. Sixteen tumors from each mouse were analyzed, except for 124m mouse from which 14 tumors were analyzed.

^3)^ The number indicates a position of a mutation site. The numbers correspond to nucleotide sequence of *APC* deposited in GenBank (Accession: NC_000084).

^4)^ The number indicates a position of a changed amino acid. X represents a nonsense codon. The numbers correspond to amino acid numbers of APC deposited in GenBank (Accession: NP_031488).

^5)^ Sequence context surrounding G:C to T:A mutations. G shown in bold indicates the mutation site. GAA sequence is underlined. Sequence of non-transcribed strand is italicized.

###### 

Mutation analysis for *Ctnnb1*

  Genotype            Amino acid change^1)^   Nucleic acid change^2)^      Sequence context^3)^       Number of mutations
  ------------------- ----------------------- ---------------------------- -------------------------- ---------------------
  Wild type           37S→F                   17219C→T                     *A**[G]{.ul}**[AA]{.ul}*   1
  41T→I               17231C→T                A**C**CA                     1                          
  del (31-39)^4)^     24-bp deletion          \-                           1                          
                                                                                                      
  *Mutyh*-deficient   32D→V                   17204A→T                     G**A**TT                   1
  33S→Y               17207C→A                A***[G]{.ul}****[AA]{.ul}*   26                         
  34G→V               17210G→T                G**[G]{.ul}**[AA]{.ul}       1                          
  37S→Y               17219C→A                A***[G]{.ul}****[AA]{.ul}*   8                          

^1)^ The number indicates a position of a changed amino acid. The numbers correspond to amino acid numbers of β-catenin deposited in GenBank (Accession: NP_001159374).

^2)^ The number indicates a position of a mutation site. The numbers correspond to nucleotide sequence of *Ctnnb1* deposited in GenBank (Accession: NC_000075).

^3)^ Sequence context surrounding G:C to T:A mutations. Letters shown in bold indicate the mutation site. GAA sequence is underlined. Sequence of non-transcribed strand is italicized.

^4)^ Nine amino acids from no.31 to 39 were replaced by newly arisen one serine resulted from the 24-bp deletion.
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